Home
Edgewise Therapeutics

Edgewise Therapeutics Market Share Analysis for August 2026

See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.

Health > Biotechnology and Pharmaceuticals

Domainedgewisetx.com

Year Founded2017

Employees51 - 200

Annual Revenue--

Edgewise Therapeutics

Edgewise Therapeutics (including company regionals)

edgewisetx.com

See more website traffic and engagement information

Total visits to Edgewise Therapeutics's top domains

Understand Edgewise Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

edgewisetx.com12.3K

See more with Sales Intelligence

Avg. visit duration in Edgewise Therapeutics's top domains

Analyze Edgewise Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

edgewisetx.com00:00:15

See more with Sales Intelligence

Avg. pageviews on Edgewise Therapeutics's top domains

See how Edgewise Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

edgewisetx.com1.69

See more with Sales Intelligence

Edgewise Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Edgewise Therapeutics

These are the website technologies, by industry, used by Edgewise Therapeutics top domains

Payment & Currencies (10)

Cart Functionality

eCommerce (6)

WooCommerce

Content Management System (5)

WordPress

Widget (4)

Twemoji

More Technologies

14

See all

News & Signals from Edgewise Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsEdgewise Therapeutics, Inc. sold assets to Servier Group in the amount of $2.65B on Jul 13th '26.SURESNES, France, July 13, 2026 /CNW/ - Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX), for up to $2.65 billion, including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments.

NewsEdgewise Therapeutics, Inc. identified as competitor of Cytokinetics on May 1st '26.Edgewise Therapeutics has reported phase 2 data on its cardiomyopathy prospect, keeping the biotech on track to start pivotal development of a would-be challenger to Bristol Myers Squibb and Cytokinetics.

NewsEdgewise Therapeutics, Inc. identified as competitor of Bristol-Myers Squibb Co on Jun 16th '26.Edgewise data power rival to BMS and Cytokinetics toward phase 3